The Mainz biotech company Biontech is targeting the next widespread disease after the corona virus.
An mRNA vaccine should also help with this.
Mainz - The Mainz company Biontech wants to develop an mRNA vaccine against malaria in the coming years.
The company announced on Monday that the start of a clinical study is planned by the end of 2022.
An mRNA vaccine contains the blueprint for part of the pathogen, so the body can develop protection against it.
The company is already using the process in the fight against the corona virus.
Biontech * announced that they want to develop a safe and highly effective mRNA vaccine with longer-lasting immunity for the prevention of malaria.
In addition, possibilities are being examined to set up production facilities in Africa that can produce mRNA-based vaccines.
Malaria is one of the most dangerous infectious diseases in the world: In 2019, the WHO registered 229 million diseases and more than 400,000 deaths, most of them children under the age of five.
Researchers have been looking for a reliable vaccine for decades - but no drug has yet been approved.
(dpa) * Merkur.de is part of IPPEN.MEDIA.
